Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Connective Tissues Proper01:25

Overview of Connective Tissues Proper

9.9K
Connective tissue proper is a class of connective tissue that encompasses all mature connective tissues except bone, cartilage, blood, and lymph. This extensive class of tissues has two subclasses — loose and dense connective tissues — classified based on the protein fiber arrangement and the amount of ground substance. 
The loose connective tissues have a meshwork of thin collagen and elastin fibers, which provide tensile strength for support and enough elasticity to move...
9.9K
Layers of Connective Tissue Proper01:21

Layers of Connective Tissue Proper

3.6K
Fascia, a thin layer of fibrous connective tissue, is distributed throughout the body. It demarcates and forms a supportive covering over skeletal muscles, bones, blood vessels, and organs. There are three main types of facia— superficial fascia, deep fascia, and subserous fascia. These are all present at different depths in the body. Fascia reduces the friction and permits muscles, joints, and organs to easily slide against each other, facilitating movement of the body and preventing...
3.6K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

601
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
601
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

2.9K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.9K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.7K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

797
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
797

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy outcomes following Eslicarbazepine acetate exposure in women with epilepsy: A global safety database analysis from clinical development to 16 years of post-marketing experience.

Seizure·2026
Same author

MaTrICS: Micromobility Associated With Trauma and Its Clinical and Socioeconomic Impact.

Cureus·2026
Same author

[A perspective on the year 2025 by hospital internists].

Revue medicale suisse·2026
Same author

Limitation of therapeutic efforts in internal medicine: a retrospective analysis of evolution and determinants (2013-2023) in a Swiss university hospital.

Swiss medical weekly·2025
Same author

Abstractive summarization through the prism of decoding strategies.

Neural networks : the official journal of the International Neural Network Society·2025
Same author

Revue medicale suisse·2025
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Feb 2, 2026

Proper Care and Cleaning of the Microscope
04:57

Proper Care and Cleaning of the Microscope

Published on: August 11, 2008

45.4K

[How to properly use beta-blockers ?]

Diogo Lopes1, Claudio Sartori2

  • 1Service de médecine intensive, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|November 22, 2018
PubMed
Summary
This summary is machine-generated.

Choosing the right beta-blocker (BB) is crucial for optimizing treatment. Understanding individual drug properties helps tailor BB selection for polymorbid patients, even with conditions like metabolic syndrome or COPD.

More Related Videos

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

14.0K
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.5K

Related Experiment Videos

Last Updated: Feb 2, 2026

Proper Care and Cleaning of the Microscope
04:57

Proper Care and Cleaning of the Microscope

Published on: August 11, 2008

45.4K
Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

14.0K
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.5K

Area of Science:

  • Pharmacology
  • Cardiology
  • Internal Medicine

Background:

  • Beta-blockers (BBs) are widely used drugs since the 1950s.
  • They represent a large and diverse class of medications with numerous clinical applications.
  • Their daily use necessitates careful consideration for optimal patient outcomes.

Purpose of the Study:

  • To evaluate the appropriateness of current beta-blocker selection for various indications.
  • To highlight the importance of understanding individual BB properties for optimizing therapy.
  • To address BB use in polymorbid patients with potential contraindications.

Main Methods:

  • Review of existing literature on beta-blocker pharmacology.
  • Analysis of BB properties: bioavailability, cardioselectivity, vasodilator, and metabolic effects.
  • Examination of clinical guidelines and evidence for BB use in specific patient populations.

Main Results:

  • Beta-blockers exhibit significant heterogeneity in their pharmacological profiles.
  • Individual properties influence BB efficacy and safety across different clinical scenarios.
  • Polymorbid patients with metabolic syndrome, peripheral arteriopathy, or respiratory diseases present unique challenges for BB selection.

Conclusions:

  • Optimizing beta-blocker therapy requires a deeper understanding of individual drug characteristics.
  • Tailoring BB selection can enhance clinical benefits, particularly in complex patient profiles.
  • Further research is needed to refine BB choice in polymorbid individuals and address perceived contraindications.